Stock Events

Stock Events

Cardiol Therapeutics 

$1.43
83
+$0.03+2.12% Today

Statistics

Day High
1.46
Day Low
1.35
52W High
1.53
52W Low
0.93
Volume
763,048
Avg. Volume
589,930
Mkt Cap
125.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.19
-0.15
-0.11
-0.07
Expected EPS
-0.089077638816
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-52.2MNet Income

Analyst Ratings

8.5Average Price Target
The highest estimate is 9.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRDL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap189.22B
Amgen is a biotech company that develops treatments for cardiovascular diseases, directly competing with Cardiol Therapeutics' focus on heart disease therapies.
Pfizer
PFE
Mkt Cap153.13B
Pfizer develops a wide range of medications, including those for cardiovascular health, making it a competitor in the same therapeutic area as Cardiol Therapeutics.
Merck
MRK
Mkt Cap300.2B
Merck produces various cardiovascular drugs, competing in the same market as Cardiol Therapeutics.
Novartis
NVS
Mkt Cap297.35B
Novartis offers a portfolio of medicines for cardiovascular diseases, directly competing with Cardiol Therapeutics in the heart disease treatment space.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb has a strong presence in the cardiovascular drug market, making it a direct competitor to Cardiol Therapeutics.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie, through its acquisition of Allergan, has expanded its portfolio to include treatments for cardiovascular diseases, competing with Cardiol Therapeutics.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, known for its work in antiviral drugs, also focuses on cardiovascular conditions, positioning it as a competitor to Cardiol Therapeutics.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca has a significant portfolio of cardiovascular drugs, making it a direct competitor to Cardiol Therapeutics in the market for heart disease treatments.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical division Janssen, develops medications for cardiovascular diseases, competing with Cardiol Therapeutics.
Sanofi
SNY
Mkt Cap113.88B
Sanofi has a diversified healthcare portfolio that includes cardiovascular drugs, making it a competitor to Cardiol Therapeutics in the heart disease treatment market.

About

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Show more...
CEO
Mr. David G. Elsley MBA
Employees
18
Country
Canada
ISIN
CA14161Y2006

Listings

MU
DE
CT9.MU
STU
DE
CT9.STU
XNAS
US
CRDL
TO
CA
CRDL.TO

0 Comments

Share your thoughts

FAQ

What is Cardiol Therapeutics stock price today?▼
The current price of CRDL is $1.43 USD — it has increased by +2.12% in the past 24 hours. Watch Cardiol Therapeutics stock price performance more closely on the chart.
What is Cardiol Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cardiol Therapeutics stocks are traded under the ticker CRDL.
Is Cardiol Therapeutics stock price growing?▼
CRDL stock has risen by +9.69% compared to the previous week, the month change is a +38.73% rise, over the last year Cardiol Therapeutics has showed a +33.49% increase.
What is Cardiol Therapeutics market cap?▼
Today Cardiol Therapeutics has the market capitalization of 125.04M
When is the next Cardiol Therapeutics earnings date?▼
Cardiol Therapeutics is going to release the next earnings report on May 19, 2026.
What were Cardiol Therapeutics earnings last quarter?▼
CRDL earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.08 USD resulting in a +38.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cardiol Therapeutics revenue for the last year?▼
Cardiol Therapeutics revenue for the last year amounts to 0 USD.
What is Cardiol Therapeutics net income for the last year?▼
CRDL net income for the last year is -52.2M USD.
How many employees does Cardiol Therapeutics have?▼
As of April 15, 2026, the company has 18 employees.
In which sector is Cardiol Therapeutics located?▼
Cardiol Therapeutics operates in the Health & Wellness sector.
When did Cardiol Therapeutics complete a stock split?▼
Cardiol Therapeutics has not had any recent stock splits.
Where is Cardiol Therapeutics headquartered?▼
Cardiol Therapeutics is headquartered in Oakville, Canada.